Will BIIB Bounce After Today's Disaster?

Insiders' Blog Commentary : Biogen Idec (Nasdaq: BIIB) is looking like a possible dead-cat bounce play after today's 45% sell-off on the Tysabri fallout. The stock is currently at $36.57/share. We view the litigation risk as minimal. Stock should be worth in low-$40s without the drug.

You May Also Be Interested In

• Wolfe Research Upgrades Biogen (BIIB) to Outperform
• Home Depot Q2 earnings preview: Signs of home-improvement demand recovery in focus
• Mizuho TMT specialist flags 2 tech stocks to buy